Australia markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
85.68+0.53 (+0.62%)
At close: 04:00PM EST
83.26 -2.42 (-2.82%)
Pre-market: 05:32AM EST

Fulgent Genetics, Inc.

4978 Santa Anita Avenue
Temple City, CA 91780
United States
626 350 0537

Sector(s):Β Healthcare
Industry:Β Diagnostics & Research
Full-time employees:Β 480

Key executives

NameTitlePayExercisedYear born
Mr. Ming HsiehChairman, CEO & Pres248kN/A1956
Mr. Paul KimChief Financial Officer253.66kN/A1967
Mr. Jian XieChief Operating Officer224.54kN/A1966
Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G.Chief Scientific Officer & Laboratory Director223.51kN/A1967
Mr. Brandon PerthuisChief Commercial OfficerN/AN/AN/A
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/AN/A1957
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities; and has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.